Top Companies in the Pharmaceutical Excipients

The global pharmaceutical excipients market is projected to reach 14.9 billion by 2030 from USD 11.0 billion in 2025 at a CAGR of 6.1% from 2025 to 2030. The growth of the pharmaceutical excipients market can be driven by increasing demand for pharmaceutical products & generics, rising adoption of novel excipient development, shift toward the development of more patient-centric formulations, and collaboration of pharmaceutical companies to deliver customized excipients.

Several key players in the pharmaceutical excipients industry with a strong global footprint include International Flavors & Fragrances Inc. (US), Archer Daniels Midland (ADM) (US), Ashland Inc. (US), Evonik Industries AG (Germany), BASF SE (Germany), Kerry Group Plc (Ireland), Roquette Frères (France), Associated British Foods Plc (UK), ADM (US) and Wacker Chemie AG (Germany) among others. Companies operating in this sector are employing various organic and inorganic growth strategies to strengthen their international presence and reinforce market positions. For instance, in May 2025, Roquette announced the successful completion of its acquisition of IFF Pharma Solutions. As a result of this acquisition, Roquette decisively strengthens its position as a key player in the health industry by integrating IFF Pharma Solutions’ expertise and innovative product portfolio of pharmaceutical excipients. Additionally, market players like Gattefossé and BASF have pursued innovation by developing multifunctional, high-performance excipients. Meanwhile, other players such as Colorcon and DFE Pharma have focused on cost efficiency and scalability, catering to generic drug manufacturers with standardized, affordable excipients to maintain competitive pricing in high-volume markets.

To know about the assumptions considered for the study download the pdf brochure

International Flavors & Fragrances Inc. (IFF)

International Flavors & Fragrances Inc. (IFF) is a prominent entity within the pharmaceutical excipients market and is a leading manufacturer of flavors, fragrances, and specialty ingredients used across various industries, such as pharmaceuticals, food, beverages, and personal care. The company operates through four key segments: Nourish, Health & Biosciences, Scent, and Pharma Solutions. In 2024, IFF maintained a strong position in the pharmaceutical excipients market, supported by a broad and diverse product portfolio. Its extensive global presence spans over 45 countries, enabling wide market access. IFF places a high priority on innovation and research, investing significantly in R&D to strengthen its product offerings and meet evolving industry demands. This strategic focus reinforces its leadership in the pharmaceutical ingredients industry.

Archer Daniels Midland (ADM) (US)

Archer Daniels Midland (ADM) (US) solidified its status as a significant player in the pharmaceutical excipients market, driven by its diversified product portfolio, high-quality standards, and strategic investments. ADM supplies a broad range of pharmaceutical-grade excipients such as ethanol, sorbitol, dextrose, starches, citric acid, and various plant-derived oils, all of which are compliant with global pharmacopeia standards (USP/NF, EP, JP). These excipients are widely used in oral solid dosage forms, liquid formulations, and topical drugs. ADM’s ability to consistently meet stringent regulatory and quality standards, including ISO-9001, IPEC-GMP, FDA-audited facilities, and RSPO-certified ingredients, makes it a preferred supplier among pharmaceutical manufacturers globally. Strategically, ADM continues to invest in expanding its pharmaceutical and wellness-focused capabilities, including its facility in Valencia, Spain, which was expanded in 2022 to boost the production of probiotics and postbiotics, an area that is gaining relevance in drug delivery systems.

MARKET RANKING

The pharmaceutical excipients market is highly fragmented, with major players such as International Flavors & Fragrances Inc. (US), Archer Daniels Midland (ADM) (US), Roquette Frères (France), BASF SE (Germany), Evonik Industries AG (Germany), Kerry Group PLC (Ireland), and Ashland Inc. (US). These companies collectively account for a significant portion of global revenues, estimated between 30% and 40% of the total market. These companies maintain their leading positions through strategic investments, regulatory approvals, technological innovation, and robust global partnerships.

Companies such as International Flavors & Fragrances (IFF), Archer Daniels Midland (ADM), and Roquette Frères are at the forefront, each offering differentiated capabilities. Following its integration with DuPont’s Nutrition & Biosciences division, IFF brings a strong portfolio of cellulose-based and marine-derived excipients such as Avicel targeting solid oral dosage forms and patient-friendly formulations. ADM leverages its strength in plant-based, naturally sourced ingredients to supply essential excipients like starches, dextrose, and glycerin, appealing to the rising demand for clean-label and nutraceutical-compatible solutions. With its well-established starch and polyol expertise, Roquette continues to innovate through solutions such as LYCAGEL for softgels and patient-centric formulations, especially gaining traction in emerging and wellness-driven markets.

BASF SE, Evonik Industries, and Ashland Inc. focus on more specialized, technology-driven excipient solutions. BASF stands out in solubility and bioavailability enhancement technologies such as hot melt extrusion. Evonik dominates the market for functional coatings with its EUDRAGIT range and supports advanced formulation development through integrated CDMO services. With its broad polymer portfolio including Klucel and Plasdone, Ashland plays a critical role in enabling modified-release and orally disintegrating dosage forms. These companies are strategically focused on delivering high-performance, compliant, and value-added excipients underpinning the pharmaceutical industry’s shift toward innovation, patient-centricity, and global formulation standardization.

The pharmaceutical excipients market remains largely fragmented, with other regional and emerging players accounting for approximately 60% to 70% of the market share. These companies are steadily strengthening their positions through strategic collaborations, partnerships, and a focus on technological innovation. Evolving industry dynamics, such as advancements in excipient technologies, shifting regulatory requirements, and the rising demand for non-invasive and personalized therapies, are reshaping the market landscape. To remain competitive, excipient manufacturers must prioritize innovation, scalability, and adaptability, especially in areas like tailored and multifunctional excipient solutions that address unmet formulation needs.

Related Reports:

Pharmaceutical Excipients Market by Product ((Organic (Oleochemicals, Cellulose, Glycols), Inorganic)), Functionality (Fillers & Diluents, Binders, Lubricants), Formulation (Oral, Parenteral), Functionality Application (Stabilizers) - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com